紫铆因对骨肉瘤细胞凋亡和转移的影响及其机制

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1730 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：研究不同浓度的紫铆因对U2OS骨肉瘤细胞的凋亡及侵袭转移作用的影响，并探讨其相关的作用机制。方法：U2OS骨肉瘤细胞在不同浓度的紫铆因作用下处理24 h，CCK-8细胞活性试剂盒测定U2OS骨肉瘤细胞活性的变化；Western blot法测定U2OS骨肉瘤细胞中凋亡相关蛋白Bax、Bcl-2，侵袭转移相关蛋白MMP-2、MMP-9，PI3K-Akt细胞信号通路相关蛋白的表达情况；Tunel法检测U2OS细胞的凋亡情况。结果：25、50、100 μmol/L紫铆因处理组与0 μmol/L紫铆因组比，细胞活性差异均有统计学意义（P＜0.05）；50、100 μmol/L紫铆因处理组与0 μmol/L紫铆因组比，Bax的表达量增加，Bcl-2、MMP-2、MMP-9表达量降低，PI3K-Akt信号通路相关蛋白表达量下降，差异均有统计学意义（P＜0.05）。结论：紫铆因可以促进U2OS骨肉瘤的凋亡并抑制其侵袭转移，这种作用可能是通过抑制PI3K-Akt信号通路来实现的。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	林增
	潘天龙
	吴登颖
	康晓雕
	蔡宁宇
	潘骏

关键词 ：紫铆因, U2OS, 凋亡, 侵袭, 转移

Abstract：Objective: To study the effects of Butein on apoptosis and invasion and metastasis of U2OS osteosarcoma cells. Methods: U2OS osteosarcoma cells were treated with different doses of Butein for 24 h respectively. CCK-8 assay was used to detect the activity of U2OS cells. Western blot assay was used to detect the expression of Bcl-2, Bax, MMP-2, MMP-9, and the PI3K-Akt signaling pathway related proteins. The TUNEL assay was used to detect the apoptosis of U2OS osteosarcoma cells. The above experiments were repeated three times to ensure the accuracy of the experimental results. Results: After U2OS osteosarcoma cells were treated with Butein, the cell activity of U2OS osteosarcoma was decreased significantly. The expression of Bax proteinwas increased, while the expression of Bcl-2, MMP-2 and MMP-9 was decreased. In addition, when U2OS osteosarcoma cells were treated with Butein, the expression of PI3K-Akt signaling pathway was decreased. Conclusion: Butein promotes the apoptosis of U2OS osteosarcoma and suppresses its invasion and metastasis. The results may suggest that Butein exhibits antitumor activities by suppressing the PI3K-Akt signaling pathway.

Key words： Butein U2OS apoptosis invasion metastasis

收稿日期: 2018-06-11

通讯作者: 潘骏，主任医师，Email：panjun@wmu.edu.cn

作者简介: 林增（1993-），男，浙江泰顺人，硕士生。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2018/V48/I12/917

[1] BIELACK S S, HECKER-NOLTING S, BLATTMANN C, et al. Advances in the management of osteosarcoma[J]. F1000Res, 2016, 5: 2767.
[2] ZHANG J, ZHU X, LI H Y, et al. Piperine inhibits proliferation of human osteosarcoma cells via G2/M phase arrest and metastasis by suppressing MMP-2/-9 expression[J]. Int Immuno pharmacol, 2015, 24(1): 50-58.
[3] ZHOU W, HAO M, DU X, et al. Advances in targeted therapy for osteosarcoma[J]. Discov Med, 2014, 17(96): 301-307.
[4] HANAHAN D, WEINBERG R A.The hallmarks of cancer [J]. Cell, 2000, 100(1): 57-70.
[5] BIELACK S, KEMPF-BIELACK B, VON KALLE T, et al. Controversies in childhood osteosarcoma[J]. Minerva Pediatr, 2013, 65(2): 125-148.
[6] CHO S G, WOO S M, KO S G. Butein suppresses breast cancer growth by reducing a production of intracellular reactive oxygen species[J]. J Exp Clin Cancer Res, 2014, 33(1): 51.
[7] RAJENDRAN P, ONGT H, CHEN L, et al. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo[J]. Clin Cancer Res, 2011, 17(6): 1425-1439.
[8] MOOND O, KIMM O, CHOIY H, et al. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation[J]. Mol Cancer Ther, 2010, 9(6):1583-1595.
[9] LI X, WU J F. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs)[J]. Recent Pat Anticancer Drug Discov, 2010, 5(2): 109-141.
[10] ZHOU J, ZHU P, JIANG J L, et al. Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1[J]. BMC Cell Biol, 2005, 6(1): 25.
[11] HWANG Y P, YUN H J, KIM H G, et al. Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by piperine via the inhibition of PKCalpha/ERK1/2-dependent matrix metalloproteinase-9 expression[J]. Toxicol Lett, 2011, 203(1): 9-19.
[12] 吕晨, 陈鑫, 朱雄白, 等. miR-21在人骨肉瘤细胞系U2OS体外侵袭中的作用及其机制[J]. 温州医科大学学报, 2017, 47(7): 490-495.
[13] ZHAN G J, YU X H, YAN Y G, et al. PI3K/Akt signaling in osteosarcoma[J]. Clin Chim Acta, 2015, 444: 182-192.
[14] YUAN T L, CANTLEY L C. PI3K pathway alterations in cancer: variations on a theme[J]. Oncogene, 2008, 27(41): 5497-5510.
[15] ZHOU W, HAO M, DU X, et al. Advances in targeted therapy for osteosarcoma[J]. Discov Med, 2014, 17(96): 301-307.
[16] XU Q, MA J, LEI J, et al. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway[J]. Biomed Res Int, 2014, 2014: 546353-546354.